Psychometric Properties of the Scale for Subjective Somatic and Cognitive Complaints of Psychotropic Medication Adult-Aged-Spectrum (SCOPA)

IF 1.7 4区医学 Q3 CLINICAL NEUROLOGY

Human Psychopharmacology: Clinical and Experimental Pub Date : 2025-07-09 DOI:10.1002/hup.70009

Levi J. M. Schuurman, Sjacko Sobczak, Julie E. M. Schulkens, Benno P. F. Balter, Sebastiaan P. J. van Alphen

{"title":"Psychometric Properties of the Scale for Subjective Somatic and Cognitive Complaints of Psychotropic Medication Adult-Aged-Spectrum (SCOPA)","authors":"Levi J. M. Schuurman, Sjacko Sobczak, Julie E. M. Schulkens, Benno P. F. Balter, Sebastiaan P. J. van Alphen","doi":"10.1002/hup.70009","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Objective</h3>\n \n <p>Patient-reported side-effect questionnaires contribute to balanced decisions regarding treatment strategy among patients with mental health disorders. However, current side-effect questionnaires are less suitable for older adults because they often lack age-specific side effects. Therefore, the Scale for Subjective Somatic and Cognitive Complaints of Psychotropic Medication Adult-Aged-Spectrum (SCOPA) was developed to quantify psychotropic side effects across the full adult age spectrum. The aim of this study was to develop and evaluate the reliability and validity of the SCOPA.</p>\n </section>\n \n <section>\n \n <h3> Procedures</h3>\n \n <p>Psychometric properties of the SCOPA were assessed in a Dutch patient population (<i>n</i> = 205, age 18–86 years) and a general population (<i>n</i> = 281, age 18–87 years). Reliability of the subscales was measured through average inter-item correlation and Cronbach's alphas. Construct validity was analysed by exploratory factor analysis.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>Average inter-item correlation and Cronbach's alphas of the subscales of the SCOPA were moderate to good. Exploratory factor analyses supported a two-factor solution, labelled as complaints in somatic and cognitive domains.</p>\n </section>\n \n <section>\n \n <h3> Conclusions</h3>\n \n <p>This study showed that the SCOPA has promising psychometric qualities and practical capability to evaluate the side-effect burden of treatment with psychotropic medication across the adult-aged-spectrum. However, more research is needed to cross-validate these results in the field's pursuit of increased patient safety.</p>\n </section>\n </div>","PeriodicalId":13030,"journal":{"name":"Human Psychopharmacology: Clinical and Experimental","volume":"40 4","pages":""},"PeriodicalIF":1.7000,"publicationDate":"2025-07-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/hup.70009","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Human Psychopharmacology: Clinical and Experimental","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/hup.70009","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Objective

Patient-reported side-effect questionnaires contribute to balanced decisions regarding treatment strategy among patients with mental health disorders. However, current side-effect questionnaires are less suitable for older adults because they often lack age-specific side effects. Therefore, the Scale for Subjective Somatic and Cognitive Complaints of Psychotropic Medication Adult-Aged-Spectrum (SCOPA) was developed to quantify psychotropic side effects across the full adult age spectrum. The aim of this study was to develop and evaluate the reliability and validity of the SCOPA.

Procedures

Psychometric properties of the SCOPA were assessed in a Dutch patient population (n = 205, age 18–86 years) and a general population (n = 281, age 18–87 years). Reliability of the subscales was measured through average inter-item correlation and Cronbach's alphas. Construct validity was analysed by exploratory factor analysis.

Results

Average inter-item correlation and Cronbach's alphas of the subscales of the SCOPA were moderate to good. Exploratory factor analyses supported a two-factor solution, labelled as complaints in somatic and cognitive domains.

Conclusions

This study showed that the SCOPA has promising psychometric qualities and practical capability to evaluate the side-effect burden of treatment with psychotropic medication across the adult-aged-spectrum. However, more research is needed to cross-validate these results in the field's pursuit of increased patient safety.

查看原文本刊更多论文

精神药物成人年龄谱主观躯体和认知主诉量表的心理测量特征

目的：患者报告的副作用问卷有助于心理健康障碍患者治疗策略的平衡决策。然而，目前的副作用调查问卷不太适合老年人，因为它们往往缺乏针对年龄的副作用。因此，制定了精神药物成人年龄谱主观躯体和认知主诉量表（SCOPA）来量化整个成人年龄谱的精神药物副作用。本研究的目的是开发和评估SCOPA的信度和效度。在荷兰患者群体（n = 205，年龄18-86岁）和普通人群（n = 281，年龄18-87岁）中评估SCOPA的心理测量特性。子量表的信度通过平均项目间相关和Cronbach’s alpha来测量。采用探索性因子分析分析构念效度。结果SCOPA各分量表的平均项目间相关系数和Cronbach's alpha均为中等至良好。探索性因素分析支持双因素解决方案，标记为身体和认知领域的投诉。结论本研究表明SCOPA具有良好的心理测量质量和实用能力，可用于评估成人精神药物治疗的副作用负担。然而，需要更多的研究来交叉验证这些结果，以提高患者的安全性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Human Psychopharmacology: Clinical and Experimental 医学-精神病学

CiteScore

4.10

自引率

0.00%

发文量

审稿时长

6-12 weeks

期刊介绍： Human Psychopharmacology: Clinical and Experimental provides a forum for the evaluation of clinical and experimental research on both new and established psychotropic medicines. Experimental studies of other centrally active drugs, including herbal products, in clinical, social and psychological contexts, as well as clinical/scientific papers on drugs of abuse and drug dependency will also be considered. While the primary purpose of the Journal is to publish the results of clinical research, the results of animal studies relevant to human psychopharmacology are welcome. The following topics are of special interest to the editors and readers of the Journal: -All aspects of clinical psychopharmacology- Efficacy and safety studies of novel and standard psychotropic drugs- Studies of the adverse effects of psychotropic drugs- Effects of psychotropic drugs on normal physiological processes- Geriatric and paediatric psychopharmacology- Ethical and psychosocial aspects of drug use and misuse- Psychopharmacological aspects of sleep and chronobiology- Neuroimaging and psychoactive drugs- Phytopharmacology and psychoactive substances- Drug treatment of neurological disorders- Mechanisms of action of psychotropic drugs- Ethnopsychopharmacology- Pharmacogenetic aspects of mental illness and drug response- Psychometrics: psychopharmacological methods and experimental design